ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1616

Region-Specific Differences in Clinical Presentation of Patients with Axial Spondyloarthritis – Results from a Large Multinational Cohort Study

Denis Poddubnyy1, Robert D Inman2, Joachim Sieper1, Fabiana Ganz3 and Maja Hojnik4, 1Charité Universitätsmeidzin Berlin, Berlin, Germany, 2Department of Medicine, University of Toronto, Toronto, ON, Canada, 3AbbVie, Baar, Switzerland, 4AbbVie, Ljubljana, Slovenia

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: axial spondyloarthritis, Multicenter study, observation and phenotypes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

There is limited evidence on the phenotypic characteristics of axial spondyloarthritis (axSpA) patients (pts) in various geographic regions around the world. This analysis aimed to compare demographic and disease-related characteristics in axSpA pts included in PROOF study in different regions.

Methods:

PROOF is an ongoing 5-year prospective observational study in pts with recently (≤1year prior to study enrollment) diagnosed axSpA and fulfilling the ASAS classification criteria. Baseline data of pts with centrally confirmed sub-classification as non-radiographic (nr)-axSpA or radiographic (r)-axSpA, based on the absence or presence of definite radiographic sacroiliitis (≥grade 2 bilaterally or ≥grade 3 unilaterally), were considered in the current analyses. Twenty-nine participating countries were divided into 4 geographic regions: 1. Europe and Canada (EC), 2. Middle East and South Africa (MEA), 3. Asia (China only), and 4. Latin America (LA).

Results:

A total of 1583 axSpA pts were centrally sub-classified as nr‑axSpA (n=544) or r-axSpA (n=1039). The proportion of patients with r-axSpA was highest in China (81%), followed by MEA (64%), EC (61%) and LA (54%) (Table). Gender distributions were similar across the regions in nr‑axSpA (M:49% vs. F:51%), while in r-axSpA the proportions of men differed, with the highest in China (79%) and lowest in MEA (58%). In both nr-axSpA and r-axSpA, Chinese patients were the youngest, reported the shortest time since chronic back pain onset and had the highest HLA-B27 prevalence. The frequency of peripheral manifestations did not differ between nr-axSpA and r-axSpA within the regions, however significant differences were observed in the frequency between the regions: peripheral arthritis was most common in LA (>50% pts); enthesitis in LA and MEA regions (≈50%), while dactylitis was not frequent with the highest prevalence again in LA (≈12%). Similarly, the prevalence of Extra-articular manifestations (EAMs) also did not differ between nr-axSpA and r-axSpA patients within the regions. Uveitis was significantly more frequent in r-axSpA pts in LA (19%) and EC (≈12%) vs China (6%). Psoriasis was almost absent in China, and had the highest frequency in EC and LA (≈10%). There were no IBD cases reported in China, while the highest IBD prevalence was reported in EC (3 and 6% for r-axSpA and nr-axSpA, respectively). Use of NSAIDs did not differ between regions, but there were differences in the frequency of therapy with conventional DMARDs, glucocorticoids and TNF inhibitors.

 

Conclusion:

The results showed differences between axSpA phenotypes between the geographic regions: peripheral manifestations were more prevalent in LA and MEA. EAMs were least frequent in Asian (Chinese) pts who were also the youngest, had the lowest disease activity and impairment in physical function.

 



Disclosure: D. Poddubnyy, AbbVie, Janssen, MSD, Novartis, Pfizer, BMS, Boehringer, UCB and Roche, 2, 5, 8; R. D. Inman, AbbVie, Amgen, Janssen, Lilly, Novartis, and Pfizer., 2, 5, 8; J. Sieper, AbbVie, Merck, Janssen, Lilly, Novartis, Pfizer, UCB, and Roche, 2, 5, 8; F. Ganz, AbbVie Inc., 1, 3; M. Hojnik, AbbVie Inc., 1, 3.

To cite this abstract in AMA style:

Poddubnyy D, Inman RD, Sieper J, Ganz F, Hojnik M. Region-Specific Differences in Clinical Presentation of Patients with Axial Spondyloarthritis – Results from a Large Multinational Cohort Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/region-specific-differences-in-clinical-presentation-of-patients-with-axial-spondyloarthritis-results-from-a-large-multinational-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/region-specific-differences-in-clinical-presentation-of-patients-with-axial-spondyloarthritis-results-from-a-large-multinational-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology